Metastatix Inc., a Tucker, Ga.-based drug company focused on cancer and HIV, has raised $35 million in Series B funding. peHUB on Monday reported the total as $20 million, based on a regulatory filing. Frazier Healthcare Ventures led the deal, and was joined by return backers like H.I.G. Ventures, S.R. One, The Aurora Funds, Advanced Technology Development Center, CM Capital, MedImmune Ventures, Georgia Venture Partners and Centrosome Ventures. www.metastatix.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.